Advanced Biliary Tract Cancers: Novel Biomarker Strategies
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Novel Agents Being Explored in Advanced Biliary Tract Cancers
Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
Sequencing Therapy in Patients With Advanced Biliary Tract Cancers
In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy
Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
An Overview of Systemic Therapy for Advanced Biliary Tract Cancers
Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
What is the Role of Transplant in Early-Stage Biliary Tract Cancers?
Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
Treatment Options for Early-Stage Biliary Tract Cancers
Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Guidelines for Molecular Testing in Biliary Tract Cancers
Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
Biliary Tract Cancers: Staging and Clinicopathologic Features
Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Challenges in Diagnosing Biliary Tract Cancers
Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
Incidence and Risk Factors for Biliary Tract Cancers
Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
An Overview on Biliary Tract Cancers
Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
Dr. He on the Future of Durvalumab Plus Chemotherapy in Biliary Tract Cancer
Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
Dr. He on the Future of Precision Medicine in GI Malignancies
Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.
Dr. He on the Potential of Immune Checkpoint Inhibitors in GI Cancers
Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, summarizes current treatment approaches in gastrointestinal (GI) cancers.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512